1 / 21

Cancer and the Immune System

Cancer and the Immune System. Prepared by: Keerstin Throm Kevin Strozyk. Overview of Topics. Origin and Terminology Oncogenes and Cancer Induction Tumor Antigens Tumor Evasion of the Immune System Immunotherapy. Major Terminology. Benign : Tumor not capable of indefinite growth

hayden
Download Presentation

Cancer and the Immune System

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Cancer and the Immune System Prepared by: Keerstin Throm Kevin Strozyk

  2. Overview of Topics Origin and Terminology Oncogenes and Cancer Induction Tumor Antigens Tumor Evasion of the Immune System Immunotherapy

  3. Major Terminology • Benign: Tumor not capable of indefinite growth • Malignant: Invasive tumor that can grow indefinitely • Metastasis: Cancerous cells dislodged from tumor which are carried to other tissues where they proceed to proliferate. • Carcinoma: Tumor from Endodermal or Ectodermal tissue. • Leukemia/Lymphoma: Malignant tumors of the hematopoietic cells of the bone marrow. • Sarcoma: A tumor of the mesodermal connective tissues.

  4. Tumor Growth and Metastasis

  5. Oncogenes and Cancer Induction Oncogenes vs. Proto-Oncogenes • Oncogenes are the viral counterparts of cellular proto-oncogenes • High degree of homology • Both are derived from genes which encode various growth • controlling proteins. • Proto-oncogenes are capable of being converted to oncogenes • by undergoing a mutation.

  6. Conversion of Proto-Oncogenes to Oncogenes Three major mechanisms • Carginogens • Viruses • Radiation

  7. Translocation of a proto-oncogene from one • chromosomal site to another, or to a separate • chromosome, can cause a malignant transformation.

  8. Progression of Metastatic Colon Cancer • A multistep process which occurs with a series • of morphologic stages.

  9. Gene Translocation

  10. Tumor Antigens • Tumor Specific Transplantation Antigens (TSTAs): • Antigens are unique to tumor cells • Chemically, physically, or virally induced. • Tumor Associated Transplantation Antigens (TATAs): • Antigens that are not unique to tumor cells • Expression of an embryonic gene • Overexpression of a normal cellular protein

  11. Tumor Specific Transplantation Antigens

  12. Tumor Associated Transplantation Antigens Oncofetal Tumor Antigens • Normally expressed early in fetal development • When found on tumor cells, can be recognized as non-self • Alpha-fetoprotein (AFP) • Carcinoembryonic antigen (CEA) Increased Expression of Normal Antigens • Elevated expression of antigen present in a normal cell • encoded by cellular oncogenes • Neu protein expression in breast cancer cells

  13. Tumor Evasion of the Immune System Antitumor Antibodies • Act as a “blocking factor” by forming • complexes with tumor antigens. Antibodies Modulate Tumor Antigens • Disappearance of tumor antigen on • surface in response to specific antibodies Low Levels of Class I MHC Molecules • Has a profound effect on the cell-mediated • cytotoxic T cell response. Poor Costimulatory Signals • Lack of costimulatory molecules cannot • stimulate CTL response

  14. Cancer Immunotherapy Manipulation of Costimulatory Signals • Transfect genes for costimulatory signals (B7 ligand) into tumor cells • To activate CTLs. Enhancement of APC Activity • Transfect a gene for GM-CSF to increase macrophage activation Cytokine Therapy • Use of cytokines like IFN-α, -β, -γ and TNF-α, -β which have direct • antitumor activity. Monoclonal Antibodies • Can cause direct complement-mediated lysis, or can be conjugated • with an agent which can be directly delivered to the tumor cell.

More Related